Clinical trials: Psychiatric Illness
Substance Use Disorders, Behavioral Health
Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders
Mindfulness and meditation based relapse prevention has been proposed as an adjunctive approach for individuals with substance use disorders (SUDs).
- Conditions
- Substance Use Disorders, Behavioral Health, Addiction Psychological, Addiction Disorders
- Trial name
- MBRP-SUD (NCT07417579)
- Testing
- Mindfulness and Meditation-Based Relapse Prevention Program
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bout Me Healing
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to provide data on the effectiveness of the OROS Methylphenidate Hydrochloride (HCl) formulation compared to placebo and standard immediate-release Ritalin with respect to improving attention and…
- Trial name
- NCT00269776
- Testing
- OROS (methylphenidate HCl), Ritalin (methylphenidate)
- Sponsor
- Alza Corporation, DE, USA
Narcolepsy, Cataplexy
An Open Label Study of FT218 in Subjects With Narcolepsy
An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium…
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder
- Trial name
- RESTORE (NCT04451668)
- Testing
- FT218
- Where
- 29 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- Avadel
Autism Spectrum Disorder (ASD)
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)
- Trial name
- NCT05182697
- Testing
- SCI-210, Oral CBD oil
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Neurothera Labs Inc.
Major Depressive Disorder (MDD
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
- Trial name
- NCT05416762
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Schizophrenia
Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia
Observational, non-comparative, epidemiological study to collect and analyse real life data on schizophrenic patients receiving quetiapine according to the standard medical practice in Croatia.
- Trial name
- NCT00981123
- Where
- 18 sites in Croatia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Erectile Dysfunction
A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction
The purpose of this study is to evaluate the safety and effectiveness of mirodenafil in participants with erectile dysfunction.
- Trial name
- NCT01802359
- Testing
- No intervention
- Volunteers
- 379 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04659161
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 22 sites in United States
- Volunteers
- 252 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Restless Legs Syndrome
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in Restless Legs Syndrome patients.
- Trial name
- NCT00530790
- Testing
- ropinirole controlled release (CR)-RLS
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Depression, Anxiety
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's…
- Trial name
- NCT05372913
- Testing
- Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Woebot Health
Alzheimer Disease
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00104013
- Testing
- xaliproden (SR57746A)
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 1,455 people
- Sponsor
- Sanofi
Bipolar Depression
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868959
- Testing
- lurasidone
- Where
- 151 sites in United States, Canada and 13 more
- Volunteers
- 817 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alzheimer Disease
A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
- Trial name
- NCT05345509
- Testing
- Aricept Tablet, IVL3003
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Attention Deficit Hyperactivity Disorder
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the…
- Trial name
- NCT00485849
- Testing
- Atomoxetine Hydrochloride
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
A Study in Erectile Dysfunction
The purpose of this study is to determine the day of onset of efficacy of tadalafil dosed once-a-day.
- Trial name
- NCT00833638
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
- Trial name
- NCT02411526
- Testing
- ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zogenix, Inc.
Smoking Cessation, Nicotine Dependence
Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)
PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking.
- Trial name
- PRECESTO (NCT06091826)
- Testing
- NFL-101
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NFL Biosciences SAS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.